Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Non-randomised, Single Arm, Phase IIIB Switch Study: Evaluating the Clinical Benefits of Quetiapine XR in Patients With Schizophrenia and Anxiety Disorder.

NCT01672554 is registered in ClinicalTrials.gov with Corporation de Recherche en Neuropsycho Pharmacologie de Quebec as lead sponsor.

NCT NCT01672554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01672554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Non-randomised, Single Arm, Phase IIIB Switch Study: Evaluating the Clinical Benefits of Quetiapine XR in Patients With Schizophrenia and Anxiety Disorder.
Lead sponsor
Corporation de Recherche en Neuropsycho Pharmacologie de Quebec
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2008
Completion date
October 31, 2013
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, schizophrenia